drugset / Trial / NCT00162149

ATV/Ritonavir Nevirapine Interaction (USPAC)

NCT00162149

Phase 1 Completed 46 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-label

Summary

Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.

Timeline

Start
2005-10
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Subject Atazanavir Other / unclassified 400 mg Oral
Comparator Nevirapine Small molecule 200 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral